S-EPMC12127193 - A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study with Post-hoc biomarker analysis - OmicsDI

Unknown

Dataset Information

A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study with Post-hoc biomarker analysis

ABSTRACT:

SUBMITTER: Baek G

PROVIDER: S-EPMC12127193 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature